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Abstract
Background: Plasmodium falciparum Apical Membrane Antigen 1 (PfAMA1) is a candidate vaccine antigen expressed by
merozoites and sporozoites. It plays a key role in red blood cell and hepatocyte invasion that can be blocked by antibodies.
Methodology/Principal Findings: We assessed the safety and immunogenicity of recombinant PfAMA1 in a dose-
escalating, phase Ia trial. PfAMA1 FVO strain, produced in Pichia pastoris, was reconstituted at 10 mg and 50 mg doses with
three different adjuvants, Alhydrogel
TM, Montanide ISA720 and AS02 Adjuvant System. Six randomised groups of healthy
male volunteers, 8–10 volunteers each, were scheduled to receive three immunisations at 4-week intervals. Safety and
immunogenicity data were collected over one year. Transient pain was the predominant injection site reaction (80–100%).
Induration occurred in the Montanide 50 mg group, resulting in a sterile abscess in two volunteers. Systemic adverse events
occurred mainly in the AS02 groups lasting for 1–2 days. Erythema was observed in 22% of Montanide and 59% of AS02
group volunteers. After the second dose, six volunteers in the AS02 group and one in the Montanide group who reported
grade 3 erythema (.50 mm) were withdrawn as they met the stopping criteria. All adverse events resolved. There were no
vaccine-related serious adverse events. Humoral responses were highest in the AS02 groups. Antibodies showed activity in
an in vitro growth inhibition assay up to 80%. Upon stimulation with the vaccine, peripheral mononuclear cells from all
groups proliferated and secreted IFNc and IL-5 cytokines.
Conclusions/Significance: All formulations showed distinct reactogenicity profiles. All formulations with PfAMA1 were
immunogenic and induced functional antibodies.
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Introduction
In sub-Saharan Africa the burden of death and disease from
Plasmodium falciparum malaria is particularly severe. To date, there
are no approved vaccines to help reduce this burden, although a
number of candidate vaccines have been put forward. The
majority of the candidates target the pre-erythrocytic circumspor-
ozoite protein (CSP) and the merozoite proteins Merozoite Surface
Protein 1 (MSP1) and Apical Membrane Antigen 1 (AMA1)[1].
The RTS,S candidate vaccine has shown efficacy in infants and
children [2,3] and a phase III clinical trial is planned. The MSP1
and AMA1 candidate vaccines are in early stage clinical
development and efficacy trials will provide information to
determine whether these antigens are suitable targets, and whether
they can be deployed singly or as components of a multivalent
malaria vaccine.
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3960Following an infected mosquito bite, P. falciparum sporozoites
migrate to hepatocytes, each developing over a period of a week to
release several thousand merozoites. These initiate cyclical asexual
blood stage development, producing merozoites that invade
erythrocytes. AMA1 is an integral membrane protein of
merozoites and sporozoites and has a central role in parasite
invasion of erythrocytes and potentially hepatocytes that can be
inhibited by anti-AMA1 antibody [4–6]. In merozoites, AMA1 is
synthesised as an 83 kDa molecule originally localised to the
microneme. Around the time of merozoite release and the
subsequent rapid erythrocyte invasion, the protein is N-terminally
cleaved to a 66 kDa form. This translocates to the merozoite
surface and undergoes secondary proteolytic processing, shedding
soluble fragments (44 or 48 kDa) [7].
Immunisation with AMA1 can provide protection against
infection in experimental animal models, and can induce
antibodies that show functionality in in vitro growth inhibition
assays (GIA). However, AMA1 is polymorphic and immune
responses have varying degrees of strain specificity and growth
inhibition [8].
Previous Phase I trials have shown that growth inhibitory
antibodies can be induced by immunisation with PfAMA1 [9,10],
but immunogenicity varied depending on the vaccine formulation.
In particular, the choice of adjuvant has a major effect on the
safety, stability, immunogenicity and, presumably, eventual
efficacy of a vaccine [11]. Adjuvants can be tools that channel
the immune reponse to generate high levels of the desired type of
long-lived immunity. Alhydrogel
TM, an aluminum salt, is the most
widely used adjuvant in licensed human vaccines and is therefore
used as a standard to compare other adjuvants. Unfortunately, in
combination with malaria antigens, it has generally induced poor
reponses [12–15]. Montanide ISA 720, a squalene based water-in-
oil adjuvant formulation has shown promising results in previous
malaria vaccine trials [16–19], possibly due to the slow-release
capacity of the inert water-in-oil emulsion and immune stimulating
effects of its components [20]. AS02, a proprietary Adjuvant
System from GlaxoSmithKline Biologicals based on an oil-in-
water formulation, contains 50 mg each of the immunostimulants
monophosphoryl lipid A (MPL) and Quillaja saponaria 21 (QS21)
[21]. It has been used to adjuvant the RTS,S malaria candidate
vaccine that targets CSP. To date, this candidate is the only
malaria vaccine that has induced protection in adults, children and
infants in natural field trials [22–25]. When combined with
Alhydrogel
TM, RTS,S did not convey protection in a combined
phase I/IIa trial [26]. AS02 is capable of eliciting high antibody
titers along with strong cell-mediated immunity [27], both of
which are believed to contribute to the efficacy of the RTS,S
candidate vaccine [28].
Because of their central role in vaccine formulation, the
development of adjuvants and delivery systems have become
increasingly important. This study aims at comparing the safety
and immunogenicity of PfAMA1 in two dosages formulated with
three different adjuvants in a phase Ia trial.
Materials and Methods
Vaccine preparation
Clinical grade PfAMA1-FVO [25-545] was developed[29] and
produced[30] as previously reported. In brief, FVO strain
PfAMA1 was codon adapted to expression in the methylotrophic
yeast Pichia pastoris. Glycosylation sites were conservatively
mutated, and the ectodomain comprising amino acids 25–545
was expressed. PfAMA1-FVO[25-545] preparation was manufac-
tured and lyophilised according to current good manufacturing
practice in multidose vials containing either 120 mg (44 mg EDTA,
180 mg sucrose and 120 mg NaHCO3, lot B) or 62.5 mg (23 mg
EDTA, 25 mg saccharose, 226 mgK 2HPO4 and 187 mg
NaH2PO4, lot C) of AMA1 that were stored between 218uC
and 230uC and between +2 and +8uC respectively. Quality
control and stability data are described by Faber et al. [31].
Reconstitution and mixing of vaccine with adjuvant was
performed under sterile conditions under responsibility of the
hospital pharmacist.
PfAMA1 vaccine at 50 mg (high dose) and 10 mg (low dose)
PfAMA1 per injection (0.5 ml) was formulated with three different
adjuvantsand,afterpreparation,waskeptata constanttemperature
of +4uC for a maximum of six hours until injection. For the
Alhydrogel
TM formulation, 1.2 ml aluminum hydroxide suspensionat
2 mg/ml (Statens Serum Institut (SSI), Copenhagen,Denmark) was
added to the 120 mg PfAMA1 vial (lot B) to obtain a high dose
(50 mg in 0.5 ml) and 6 ml was added to obtain a low dose (10 mgi n
0.5 ml) formulation. The resulting amount of aluminum in each
vaccine was 0.5 mg. Stability studies confirmed adsorbtion of
99.9% of the antigen to the aluminum. Montanide formulations
werepreparedbydissolvingthecontentsofthe120 mg PfAMA1vial
(lot B) in sterile phosphate buffered saline (145 mM NaCl, 5 mM
Phosphate, pH 7.4), 0.32 ml for the high dose and 1.6 ml for the
low dose formulation. Montanide ISA 720 (SEPPIC, Paris, France)
was subsequently added, 0.88 ml for the high dose to obtain 1.2 ml
of formulation (50 mg PfAMA1 in 0.5 ml) and 4.4 ml for the low
dose to obtain 6 ml of formulation of which five 10 mg PfAMA1 in
0.5 ml doses could be prepared. The suspension was prepared by
manually pushing through a 22 gauge syringe coupling piece
(3038068 Omnilabo International, Breda, The Netherlands) at
+20Cu for twenty up and down strokes.
The suspension was confirmed to be homogeneous and reached
a median droplet size of approximately 1.5 mm (SD 0.17 mm) by
particle size measurements with the Malvern Mastersizer S by
SEPPIC.
For the AS02 formulation, the contents of one vial of lyophilized
PfAMA1 containing 62.5 mg of antigen (lot C) was mixed by gentle
shaking with AS02 (approximately 0.6 ml) [32]. A 0.5 ml dose
contained approximately 50 mg AMA-1 in 500 ml AS02 (high
dose). For low dose preparations (10 mg) five times more AS02
adjuvant was added to the 62.5 mg vial of AMA1, from which five
0.5 ml low vaccine doses could be obtained.
Study design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1 with Amendments S2, S3, S4, S5, S6 and S7. The
study was designed as a dose-escalating phase Ia trial to assess the
safety and immunogenicity of two dosages of PfAMA1 with three
different adjuvants. Volunteers were thus randomised into six
different groups, each of which was aimed to constitute of a limited
number of 10 volunteers for safety reasons. Randomisation was
performed by an external statistician in six blocks through a
computer program. Block randomization were used to ensure
equal distribution of adjuvants among the immunisation groups.
There was no stratification for sex and/or age. The randomization
list was provided to the pharmacy departments. The clinical
investigators allocated the next available number on entry into the
trial. The code was revealed to the researchers once recruitment,
data collection, and laboratory analyses were complete. The
immunisations were thus performed blind, so neither volunteers,
nor investigator or laboratory personnel were aware of the
adjuvant allocation. Because of the dose-escalating design, the trial
could not be blinded for dose.
PfAMA1 Phase 1 Trial
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immunised nine months after the Alhydrogel
TM and Montanide
groups, breaking the blind for this trial arm. A subsequent bias
cannot formally be excluded but seems unlikely, since all trial
procedures were identical. All immunisations were performed
intramuscularly in the deltoid region of alternate arms at 0, 4 and
8 weeks.
Participants
We aimed to recruit 60 healthy, malaria naı ¨ve male volunteers,
aged between 18 to 45 years through advertisements at the
Radboud University Nijmegen Medical Centre. Potential volun-
teers provided a medical history and a physical examination was
conducted with routine laboratory tests consisting of full blood
count, serum biochemistries and serologic assays for human
immunodeficiency virus, hepatitis C and B virus. Volunteers were
excluded from participation if they had any symptoms, signs or
laboratory values suggestive of systemic illness, including renal,
hepatic, cardiovascular, pulmonary, skin, immunodeficiency,
psychiatric and other conditions, which could interfere with the
interpretation of the study results or compromise the health of the
volunteers, or received chronic medication, had a history of drug
or alcohol abuse interfering with social function one year prior to
enrolment, or a known hypersensitivity to any of the vaccine
components. Additional reasons for exclusion were a history of
malaria or residence in malaria endemic areas within the past six
months, previous participation in a malaria vaccine trial or
receiving vaccines other than the study vaccines. Furthermore,
volunteers were not enrolled in any other clinical trial, and agreed
to remain available to be closely monitored. All volunteers
provided written informed consent. The study was approved by
the Institutional Review Board (CMO Regio Arnhem-Nijmegen,
2005/015). The study was conducted in accordance with the
Declaration of Helsinki principles for the conduct of clinical trials
and the International Committee of Harmonization Good Clinical
Practice Guidelines [33] and registered at www.clinicaltrials.gov
(NCT00730782).
Assessment of safety
Volunteers were observed for 30 minutes and evaluated on days
1, 3, 7 and 14 after every immunisation. At each visit, local and
systemic reactogenicity was assessed by a physician and findings
recorded and scored as follows: grade 1, mild reaction (easily
tolerated), grade 2, moderate reaction (interferes with normal
activity), or grade 3, severe reaction (prevents normal activity).
Redness, swelling and induration (according to Brighton collab-
oration definitions, www.brightoncollaboration.org) were mea-
sured with a ruler, and categorised according to the longest
diameter as grade 1: #20 mm, grade 2: .20 and #50 mm, grade
3: .50 mm. Temperature was measured with an oral thermom-
eter; fever intensity was defined as grade 1 (37.5uCt o3 8 uC), grade
2( .38uCt o3 9 uC) or grade 3 (.39uC). The following adverse
events were solicited and recorded routinely during the 14 days
after immunisation: injection site pain, redness and swelling,
systemic fatigue, fever, headache, malaise, myalgia, joint pain,
gastrointestinal symptoms and contralateral local reactions.
Blood samples
Safety was also determined by serial laboratory evaluations of
clinical chemistry and haematology on blood samples collected 7
and 28 days after immunisation. For evaluation of immunogenic-
ity, blood was collected in Vacutainer CPT tubes (Becton and
Dickinson) and processed within two hours after collection on
immunisation days, one month after each immunisation and on
Days 140 and 365. Plasma was collected after centrifugation
(2000 g 159) aliquoted and stored at 220uC for antibody analysis
(ELISA, Immuno Fluorescence Assay (IFA) and Growth Inhibition
Assay (GIA)). Peripheral blood mononuclear cells (PBMC) were
collected, washed in PBS (800 g, 10 min) and immediately used
for assays (lymphocyte stimulation assay and ELISPOT).
Measurement of anti-AMA1 antibodies by ELISA and IFA
Antibody to PfAMA1 was measured using a standardized ELISA
protocol. All procedures used Phosphate buffered saline (PBS) and
for washing steps 0.05% Tween 20 (Sigma-Aldrich). Briefly, wells in
96-well polystyrene plates (NUNC Maxisorp, Sanbio), were coated
overnight (100 ml, 0.5 mg/ml PfAMA1, 4uC), washed (36), blocked
(60 min,3%BSA(Sigma-Aldrich)) and washed(36) beforeaddition
of 100 mL from duplicate dilution series (diluted in PBS-Tween
BSA, one hour, +37uC). After washing (36) goat anti-human IgG
alkaline phosphate (Perbio Science) diluted 1:1250 in 0.5% BSA,
0.05% Tween was added, (one hour, +37uC). Plates were washed
and 100 ml of 1 mg/ml para-nitro-phenyl-phosphatase (Fluka,
Sigma-Aldrich) substrate was added (30 minutes, room tempera-
ture). A human plasma pool from a malaria endemic area was used
as reference positive control, whereas a plasma pool from eight
healthy malaria-naive Dutch volunteers was used as a negative
control. Optical density was measured at 405 nm. Variation
between duplicates was set to a maximum of 15%. Measurements
with a greater variation were repeated. The standard curve of
human plasma pool from a malaria endemic area, defined to
contain 400 Arbitrary Units, was fitted to a four-parameter
hyperbolic function, using the ADAMSEL program (E. Remarque,
unpublished work). Using this standard curve, optical density from
samples were converted to Arbitrary Units (AU). Test samples that
did not fall within the linear part of the optical density range of the
standard were tested at alternate dilutions.
IFA was performed on cultured P. falciparum parasitized red blood
cells. Ten well black slides (30-966-A black, Nutacon, The Nether-
lands) were coated with a washed parasite suspension of 3610
6
parasites/ml,airdriedandkeptat280uC untilused. FCR3 parasites,
expressing an AMA1 protein with one amino-acid difference from
the FVO parasites, and NF54 strain parasites, with 26 amino-acid
difference in AMA1 protein were used to prepare slides.
Based on antibody titers by ELISA on day 84, a representative
sample of fifteen sera was selected for IFA, containing at least two
samples from each adjuvant group and at least three samples with
low, intermediate or high ELISA titers. Before use slides were
brought to room temperature in an evacuated exicator. Plasma
was diluted in PBS (1:40, 1:80, 1:160, 1:320, 1:640) and a final
volume of 20 mL was added to the wells and incubated for
0.5 hour, at room temperature. As for the ELISA protocol, the
malaria-naı ¨ve blood bank donor plasma pool was used as a
negative control and human malaria endemic plasma was used as
a positive control. After washing (26in PBS) and air drying, slide
samples were incubated with rabbit anti-human Immunoglobin
FITC (F0200, DAKO, Denmark) in 0.05% w.v Evans Blue (3169,
Merck), PBS for 30 minutes at room temperature. Slides were
washed twice and incubated for 15 minutes with DAPI (49-6-
Diamindino-2-phenylindole, 24653, Merck, Darmstadt, Ger-
many), 5 mg/ml in PBS. After washing (26 in PBS) slides were
mounted with Vectashield Mounting Medium (H-1000, Brunsch-
wig, Amsterdam), covered with a deck-slide and read immediately
by two independent blinded examiners. Examiners identified the
highest dilution still showing a staining pattern above the
background of pre-immunisation samples. Differences between
examiners were never greater than one dilution and the mean of
both dilutions was taken.
PfAMA1 Phase 1 Trial
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ELISPOT was performed according to manufacturer’s instruc-
tions (Becton and Dickinson Elispot Set Human IFNc or IL-5). In
summary, plates provided in the set were coated with either IFNc
or IL-5 capture antibody (5 mg/ml, overnight, 4uC). After blocking
with complete medium solution (RPMI 1640 (Invitrogen)
containing 10% Fetal Bovine Serum (FBS Invitrogen, Breda,
The Netherlands), 1% Glutamax (Invitrogen), 1% Penicillin-
Streptomycin (GIBCO-BRL, Invitrogen), 1% MEM) 100 mlo f1 0
5
PBMC suspension and 100 mlo fPfAMA1 containing either
60 mg, 12 mg or 2.4 mg was added per well. Positive controls were
stimulated with Tetanus Toxoid 10 mg/ml (RIVM, Bilthoven,
The Netherlands) and phytohaemagglutinin 5 mg/ml (PHA-L
Sigma-Aldrich) end concentration. Negative controls were incu-
bated with complete medium solution (mean SFC/10
5 cells
31617 for IFNc and 967 for IL-5). After incubation (40 hours,
37uC in humidified 5% CO2), biotinylated anti human IFNc and
IL-5 (0.25 mg/ml and 2 mg/ml, respectively), containing 10% FBS
was added (two hours at room temperature). Streptavidin-HRP
was used as an enzyme conjugate. Detection was performed with
the Becton and Dickinson AEC Substrate Reagent Set, according
to manufacturer’s instruction. Spot-forming cell numbers were
counted by ELISPOT reader (4 Microtiter Plate Reader,
AELVIS, Sanquin, Amsterdam) and analysed by the ELISPOT
Analysis Software Version 4.0 (Sanquin, Amsterdam). All
measurements were performed in triplo. Variation between
triplicates was set to a maximum of 20%.
Lymphocyte Stimulation Assay
Lymphocyte stimulation assays were performed as described
previously [34]. Peripheral blood mononuclear cell suspension
(PBMC) was diluted to 1610
6 PBMC per ml in Dulbecco’s MEM
(DMEM) with Glutamax-I, 2 mM pyruvate and high Glucose
(GIBCO BRL, Invitrogen) supplemented with 10 mM HEPES
buffer (GIBCO BRL, Invitrogen), 100 IU/mL Penicillin-Strepto-
mycin (GIBCO BRL, Invitrogen), 100 mM non-essential aminoa-
cids (GIBCO BRL, Invitrogen) and 2.5% human AB serum (AB)
(Bodinco BV, Alkmaar, The Netherlands). 100 ml of PBMC was
added to 100 ml PfAMA1 (30, 6 or 1.2 mg/ml in PBS) in 96 well
Nunclon surface flat plates (Life Technology). Plates were incubated
(six days, +37uC, humidified 0.5%CO2) before labelling (10 ml
3H
thymidine, 0.25 uCi per well, 24 hours) and harvested onto Wallac
filter mats using the Wallac Beta plate harvester. Incorporated
3H-
thimidine was determined using a Wallac Beta Plate counter.
Stimulation indices (SI) were calculated relative to control wells to
which no PfAMA1 had been added. PBMC were tested in parallel
for their ability to be stimulated with Tetanus Toxoid (Purified
Tetanus Toxoid 150 Lf/ml, RIVM, Bilthoven, The Netherlands)
and phytohaemagglutinin 5 mg/ml (PHA-L, Sigma-Aldrich).
In vitro parasite growth inhibition
Antibodies to be used for parasite inhibition assays were purified
on protein A columns (Immunopure Plus Pierce, St Louis, MO,
USA) using standard protocols, exchanged into RPMI 1640 using
Amicon Ultra-15 concentrators (30 kDa cutoff, Millipore, Ire-
land), filter-sterilised and stored at 220uC until use. IgG
concentrations were determined using a Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Wilmington, DE,
USA).
P. falciparum strain FCR3 was cultured in vitro using standard
P.falciparum culture techniques in an atmosphere of 5% CO2,5 %
O2 and 90% N2. FCR3 AMA1 (accession no. M34553) differs by
one amino acid in the pro-sequence from FVO AMA1 (accession
no. AJ277646).
The effect of purified IgG antibodies on parasite invasion was
evaluated with two IgG concentrations (5 and 10 mg/mL,
respectively) in triplicate using 96 well flat-bottomed plates
(Greiner) with synchronized cultures of P. falciparum schizonts at
a starting parasitemia of 0.2–0.4%, a haematocrit of 2.0% and a
final volume of 100 mL containing 10% control non-immune
human serum, 20 mgm L
21 gentamicin in RPMI 1640. After 40
to 42 hours, cultures were resuspended, and 50 mL was transferred
into 200 mL ice-cold PBS. The cultures were then centrifuged, the
supernatant removed and the plates were frozen. Inhibition of
parasite growth was estimated using the pLDH assay as previously
described (14). Parasite growth inhibition, reported as a percent-
age, was calculated as follows: 1002((Odexperimental2Odbackground)/
(Odcontrol2Odbackground)6100). IgG purified from plasma before
immunisation was used as a control, and culture medium was used
to measure the background Od.
Statistical methods
Safety analyses were based on intention to treat data selection
(n=56). For immunology assays, per protocol analyses were used
(n=47). Between group differences were calculated by one-way
ANOVA, using post-hoc Bonferroni when p,0.05. Differences




Participants were recruited at the Radboud University Nijme-
gen Medical Centre from September to October 2005. Of 92 adult
males screened in and having provided informed consent, 56 were
eligible and enrolled (fig. 1). Main reasons for exclusion were
abnormal laboratory parameters or unable to be closely monitored
for social, geographic or psychological reasons. Table 1 shows the
demographics of volunteers per randomised group. The mean age
was 23 years old (range 18–42 years) and all but one were
Caucasian.
Safety and reactogenicity
No serious adverse events occurred that were definitely,
probably, or possibly related to immunisation. No clinically
relevant changes in vital signs or laboratory values were reported
throughout the study. Forty-seven volunteers (84%) received all
three immunisations; nine were excluded for one or more
immunisations (fig. 1). Two of these were excluded for reasons
unrelated to the trial procedures. One (Alhydrogel
TM 10 mg
group) developed a generalised rash assessed as unrelated to the
vaccine between the first and second immunisations and one
(Montanide 10 mg group) received a concomitant hepatitis B
immunisation. Seven volunteers were excluded because they
developed grade 3 erythema (diameter .50 mm) after the second
immunisation; one in the Montanide 10 mg group, the other six in
the AS02 groups (two in the 10 mg group, four in the 50 mg
group).
Volunteers in all groups presented with local injection site
reactions, the most predominant being transient mild to moderate
pain (80–100%, table 2). Erythema was commonly observed (10 of
17 volunteers) in the AS02 adjuvanted groups, occurring after the
second and third immunisation. In the Montanide group 4 of 18
volunteers developed erythema. Seven volunteers reported grade 3
erythema and were withdrawn from further immunisation after
dose 2. The skin in grade 3 (diameter .50 mm) erythema was not
painful and did not limit daily activities. Episodes of erythema
generally lasted 2–3 days.
PfAMA1 Phase 1 Trial
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the course of the study (table 2). One volunteer, in the Montanide
10 mg group, developed moderate induration 15 days after the first
immunisation, lasting for five days. The second and third
immunisations in this volunteer were well tolerated; induration
did not re-appear. Another volunteer developed induration
starting nine days after the first immunisation in the left arm with
50 mg PfAMA1 in Montanide, lasting 25 days. The second
immunisation was well tolerated, but the left arm induration re-
appeared one day after the third immunisation, accompanied by
pain and induration at the previous immunisation site in the
contralateral (right) arm. Four weeks later, the induration became
soft and fluctuated, indicating abcess formation. A total of 63 ml of
opaque, brown fluid was aspirated by two subsequent punctures,
after which the abscess and induration resolved spontaneously and
disappeared completely at 81 days post third immunisation. The
third volunteer, also in the 50 mg PfAMA1 adjuvanted with
Montanide group, developed moderate induration nine days after
the second immunisation which lasted approximately one week.
Six days after the third immunisation he developed induration at
his left arm (the site of the first and last immunisation) which
eventually started fluctuating. A total of 130 ml brown, opaque
fluid was collected by means of two punctures. Thereafter,
spontaneous percutaneous drainage occurred and the lesion
resolved 57 days after the third immunisation. Both volunteers
did not have any systemic symptoms such as fever during this time
period. Abcesses were only mildly painful, but limited volunteers
daily activities because of their size.
The aspirated fluids from both volunteers were abundant in red
blood cells and lymphocytes with low Creatinine Kinase (CK)
levels. Repeated cultures did not reveal any bacterial contamina-
tion. Serum CK levels were normal. Circulating levels of C-
reactive protein remained below detection levels (indicating that
the reaction was a local response). Ultrasound examination
suggested an intramuscular and subcutaneous localisation of the
fluid-filled cavity.
Systemic reactions were infrequent in the Alhydrogel
TM and
Montanide groups and occurred mainly in the AS02 groups. The
systemic adverse events occurred within 24 hours of immunisation
and usually resolved within two days. The most prevalent systemic
adverse events were headache (77.8–87.5%) and malaise (66.7–
87.5%) in the AS02 groups. Four of those volunteers reported
grade 3 headache or malaise. Most of the systemic adverse events
occurred after dose 2. There was no effect of antigen dose on
reactogenicity. No changes in blood pressure were noted in any of
these volunteers.
Figure 1. Study flow chart showing number of volunteers randomised, withdrawn and completing follow-up. Coding for adjuvant as
follows: Alum=Alhydrogel
TM, Mon=Montanide. Reasons for withdrawal are given: ‘‘rash’’=allergic rash unrelated to study procedure,
‘‘erythema’’=grade 3 injection site erythema leading to withdrawal, ‘‘other vac.’’=concomitant Hepatitis B vaccination leading to exclusion.
doi:10.1371/journal.pone.0003960.g001
Table 1. Demographic data, race and age of volunteers per
dose and adjuvant group.
Adjuvant Aluminum Montanide AS02 All
PfAMA1 dose 10 mg5 0 mg1 0 mg5 0 mg1 0 mg5 0 mg
N 1 0 1 01 09 9 8 5 6




Mean 22.4 22.6 22.5 22.6 24.1 24.4 23.0
STD 3.1 2.0 4.5 3.8 7.3 6.1 4.6
Minimum 18 19 18 19 19 18 18
Maximum 29 26 33 31 42 36 42
doi:10.1371/journal.pone.0003960.t001
PfAMA1 Phase 1 Trial
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Peak antibody titers were observed one month after the final
immunisation. 100% of volunteers in the 10 and 50 mg AS02 and
50 mg Montanide groups showed a greater than four-fold increase
in antibody titer over pre-immunisation compared to 60% in the
10 mg Alhydrogel
TM, 80% in the 50 mg Alhydrogel
TM and 90% in
the 10 mg Montanide groups (fig. 2). All vaccinees had reached IgG
titers comparable to or higher than semi immune sera. Two and
four months post final immunisation both AS02 groups and the
Montanide 50 mg group showed the highest IgG titers but given the
small sample sizes therewasno power to detectstatistical differences
between groups. Antibody titers decreased further one year post
immunisation, with the steepest decline being in the Montanide
groups, to a level comparable with the reference Alhydrogel
TM
groups. One year post vaccination, titers in the 10 mg AS02 group
were significantly higher as compared to the reference group (post
hoc Bonferroni when compared with low dose Alhydrogel
TM
reference group p,0.01, 95% CI 0.25 to1.5). Vaccinees receiving
50 mg PfAMA1 generally showed a trend towards higher antibody
titers than the corresponding 10 mg group, except for the AS02
groups where antibody titers were not antigen dose-dependent.
Sera from vaccinees could be shown to recognise the native
PfAMA1 by immunofluorescence in a dose dependent manner.
Eight of fifteen samples were positive in IFA, amongst which were
four samples with the highest antibody titers. The staining pattern
found in positive samples localised to the same structures as 4G2
rat monoclonal antibody (fig. 3).
Cellular immune response
In all groups, induction of IFNc and IL-5 cytokines could be
demonstrated (fig. 4). The magnitude of cytokine production was
not dose dependent or dependent on the number of immunisa-
tions. Rather, IFNc production in many samples decreased after
the third immunisation. For both cytokines, PfAMA1 induction
was comparable or higher than that following stimulation with
5 mg Tetanus Toxoid (data not shown). Cytokine production in
the different groups did not differ significantly from each other (for
INFc p=0.18, for IL-5 p=0.14). Ratio’s of IFNc / IL-5
production were also not significantly different between adjuvant
groups (data not shown), but showed a trend towards higher ratio
in the Montanide and AS02 groups (Day 84 mean ratio
Alhydrogel: 1.16 (95% CI: 0.08 to 2.23), Montanide: 2.82 (95%
CI: 1.44 to 4.21), AS02: 2.66 (95% CI: 0.57 to 4.76)).
All groups showed Peripheral Blood Mononuclear Cell
proliferation upon stimulation with PfAMA1 (fig. 5). Stimulation
indices between PBMC’s stimulated with 30, 6 or 1.2 mg/ml
PfAMA1 were similar. All groups of volunteers showed significant
increase in proliferation upon stimulation with PfAMA1 after the
second immunisation. After the third immunisation none of the
groups showed a further increase in stimulation index, rather the
10 mg Montanide group showed a significant decrease after the
third immunisation (p=0.03). There were no significant differ-
ences in stimulation index between the different adjuvant or dose
groups.
In vitro parasite growth inhibition
To estimate functionality of the induced antibodies, an in vitro
GIA was performed. Results are shown as percentage inhibition
compared to pre-vaccination sera from the same individual (fig. 6).
At a concentration of 10 mg/ml, the median growth inhibition in
the Montanide 50 mg and AS02 groups was about 30% and 50%
respectively. In the Alhydrogel
TM and Montanide 10 mg groups
median inhibition was lower, ranging from 4 to 17%. Only
differences between Alhydrogel
TM and AS02 groups were
significant (p=0.002).
Discussion
This trial demonstrates that reactogenicity of PfAMA1-
FVO[25-545] varies, depending on the adjuvant. Immunogenicity
Table 2. Number of volunteers reporting vaccine related adverse events per dose and adjuvant group.
Adjuvant Alum Montanide AS02 Total
PfAMA1 dose 10 mg5 0 mg1 0 mg5 0 mg1 0 mg5 0 mg
N 1 01 01 09 9 8 5 6
Total 8 (80.0%) 10 (100%) 9 (90.0%) 9 (100%) 9 (100%) 8 (100%) 53 (94.6%)
LOCAL
Pain 8 (80.0%) 10 (100%) 8 (80.0%) 9 (100%) 9 (100%) 8 (100%) 52 (92.9%)
Erythema - - 2 (20.0%) 2 (22.2%) 4 (44.4%) 6 (75.0%) 14 (25%)
Swelling - - 1 (10.0%) - 3 (33.3%) 1 (12.5%) 5 (8.9%)
Induration - - 1 (10.0%) 2 (22.2%) - - 3 (5.4%)
Sterile abscess - - - 2 (22.2%) - - 2 (3.6%)
SYSTEMIC
Headache 1 (10.0%) - 2 (20.0%) - 6 (66.7%) 7 (87.5%) 16 (28.6%)
Malaise - - - 1 (11.1%) 6 (66.7%) 7 (87.5%) 14 (25.0%)
Fever - - - - 5 (55.6%) 5 (62.5%) 10 (17.9%)
Myalgia - - - - 4 (44.4%) 2 (25.0%) 6 (10.7%)
Nausea 1 (10.0%) - - - 1 (11.1%) 2 (25.0%) 4 (7.1%)
Fatigue - - - - - 2 (25.0%) 2 (3.6%)
Arthralgia - - - - 1 (11.1%) - 1 (1.8%)
Abdominal pain - - - - 1 (11.1%) - 1 (1.8%)
doi:10.1371/journal.pone.0003960.t002
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good, although the type and magnitude of immune response
varied among different adjuvant groups.
PfAMA1-FVO[25-545] mixed with the adjuvants Alhydrogel
TM,
Montanide and AS02 tended to be locally reactogenic, mainly
causing short lasting injection site pain when administered to
Figure 2. Mean log anti-AMA-1 titers with standard error of the mean for low and high dose per adjuvant group. Anti-AMA-1 titers
were determined by ELISA for the six different groups, immunized with Alhydrogel
TM, Montanide and AS02 adjuvanted PfAMA1 vaccine. Dashed lines
represent high dose of PfAMA1 (50 mg), continuous lines represent low dose groups (10 mg). Measurements were performed at baseline, 28 days after
the first, second and third immunisation (day 28, 56 and 84 respectively) and day 140 and 365.
doi:10.1371/journal.pone.0003960.g002
Figure 3. Representative immunofluorescent microscopy picture, showing recognition of native antigen on merozoites by induced
anti-AMA1 antibodies. Immunofluorescence picture of merozoites incubated with 406diluted anti-AMA1 plasma from an immunized volunteer
one month after final immunisation stained with Rabbit anti-human immunoglobulin FITC (A) and DAPI (B). Photo was taken at magnification 4006.
Incubation with monoclonal antibody 4G2, a pan-specific anti-AMA1 antibody, confirmed the surface staining pattern (not shown).
doi:10.1371/journal.pone.0003960.g003
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PLoS ONE | www.plosone.org 8 December 2008 | Volume 3 | Issue 12 | e3960healthy adult volunteers. Most post immunisations adverse events
were mild-to-moderate in intensity and have been seen previously
with other vaccines[35–40]. Because this was the first time Pichia
Pastoris produced FVO PfAMA1 antigen was being given to
humans, the occurrence of a grade 3 adverse event was a stopping
criterium, which led to withdrawal of seven subjects post dose 2 for
grade 3 (.50 mm) erythema. However, the erythema observed
resolved spontaneously within three days of onset without any
sequelae. The erythema is not considered a hindrance for further
vaccination with the AS02 adjuvant. In terms of systemic adverse
events, most were related to the AS02 adjuvant and transient
resolving withintwodays with no sequelae. Thepatternoftransient,
primarily mild to moderate systemic adverse events has been
reported with another AMA-1 antigen adjuvanted with AS02 [41].
Three immunisations with 50 mg PfAMA1 adjuvanted by
Montanide induced a sterile abscess in two of ten volunteers.
Progression of induration to a sterile abscess has been previously
reported before after immunisation with Montanide [42–44]. In
all reports the development of an abscess followed intramuscular
immunisation and was accompanied by enhanced immunogenic-
ity. The increased reactogenicity of Montanide-adjuvanted
vaccines has been attributed to a combination of antigen dose
and the formation of a vaccine depot that may persist locally and
that is inherent to water-in-oil emulsions [45]. Similarly,
induration at the previous immunisation site has been attributed
to persistent antigen in previous trials [46]. A less condensed
vaccination regimen and avoidance of the same injection sites may
be measures to avoid induration.
To date, there are four other reports on clinical phase Ia trials of a
PfAMA1 vaccine. These trialsemployed different PfAMA1 constructs
andutilizeddifferentadjuvants.TheconstructswereofP.pastorisorE.
coli origin or used a virally vectored delivery system [47–50].
The P. pastoris-produced PfAMA1 comprised recombinant
proteins based on sequences from the ectodomains of FVO and
Figure 5. Stimulation indices in response to 6 mg/ml PfAMA1 presented as box plots and whiskers. Peripheral Blood Mononuclear Cells
from immunised volunteers 28 days after the second immunisation and 28 days after the third immunisation (Day 56 and 84 respectively) were
stimulated with 6 mgo fPfAMA1 vaccine. Cell proliferation was measured by adding
3H thymidine and calculated relative to control wells. Box plots
and whiskers show the range and the 25
th,5 0
th and 75
th percentile. Circles represent outliers. Measurements were performed at baseline, 28 days
after the second immunisation and 28 days after the third immunisation (day 56 and 84 respectively).
doi:10.1371/journal.pone.0003960.g005
Figure 4. ELISPOT assay for IFNc (A) and IL-5 (B) after stimulation with 6 mg PfAMA1. Peripheral Blood Mononuclear Cells from immunised
volunteers 28 days after the second immunisation and 28 days after the third immunisation (day 56 and 84 respectively) were stimulated with 6 mgo f




th percentile of spots per 2610
5 cells. Circles represent outliers.
doi:10.1371/journal.pone.0003960.g004
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TM have been tested
both in a phase Ia and Ib trial. As with previous studies in which
malarial antigens have been adjuvanted with Alhydrogel
TM, this
candidate vaccine showed an acceptable reactogenicity profile but
a limited immune response. The Malkin et al. phase Ia trial shows
a GIA response in only 4 of 22 subjects despite high
seroconversion rates [51], similar to the data obtained here with
Alhydrogel
TM. Interestingly, in our study, the P. pastoris PfAMA1
combined with Alhydrogel
TM was much less reactogenic and did not
produce any erythema or induration, even though the doses were
comparable. The lower Alhydrogel dose (500 mg per immunisa-
tion) used in this trial, as compared to Malkin et al. (800 mg) may
also play a role in its decreased reactogenicity.
There are two trials utilizing the E. coli-produced 3D7 strain
AMA1, one reconstituted in Montanide and a second formulated in
AS02. The AMA1-Montanide combinationwas considered safe but
the trial was compromised by apparent loss of potency [52]. The
AMA1-AS02 combination [53] showed comparable local and
systemic reactogenicity. Although Polhemus et al. were able to show
recognition of the native antigen by IFA, growth inhibition results
were approximately two fold lower than those found in this study.
Lastly, PfAMA1 has also been evaluated in a multi-antigen
malaria vaccine delivered in an attenuated vaccinia virus.
Although weak protective effects were found, immunogenicity in
that trial was poor [54].
After one year follow-up, we found antibody levels still to be
significantly higher than baseline for all groups. This is in sharp
contrast to the results of Malkin et al. [55] who reported detectable
antibodies in only 50–90% of volunteers by day 364, even though
they had been boosted much later (on Day 180). This suggests that
a more condensed immunisation regime may affect the persistence
of antibodies.
In this trial we have shown that the combination of clinical
grade PfAMA1 FVO [25-545] P. pastoris expressed material with
either Montanide or AS02 is significantly more immunogenic than
previous PfAMA1 formulations, being capable of inducing high
levels of antibodies for both dosages in both adjuvant groups. A
positive trend between antigen dose, antibody response and in vitro
parasite growth inhibition could be detected, although the effect of
antigen dose on immunogenicity was negligible compared to the
effect of varying the adjuvant. The wide variety of immune
responses found in different adjuvant formulations stresses the
importance of adjuvants as a critical component in malaria
vaccine development.
The functionality of vaccine induced antibodies was assessed by
growth inhibition assay. Although this assay has not been validated
Figure 6. Percentage of growth inhibition of FVO-strain P. falciparum parasites after addition of 5 or 10 mg/ml IgG. Serum samples
from volunteers immunised with PfAMA1 were obtained four weeks after the final immunisation by per protocol analysis and included in a merozoite
growth inhibition assay. Growth inhibition is expressed as a percentage to control.Boxes show 25
th,5 0
th and 75
th percentile growth inhibition,
whiskers show the range, circles are outliers.
doi:10.1371/journal.pone.0003960.g006
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standardised assay is able to demonstrate recognition of the native
protein and thus functionality in vitro.
Different adjuvants are known to prompt immune responses
towards Th1 or Th2. It has been previously reported that AS02
induces an immune response skewed towards Th1 [56], with
production of primarily IFNc. In contrast Alhydrogel
TM is known to
be Th2 inducer [57]. In this study, ratio’s of cytokine production
at day 84 showed relatively more IFNc over IL-5 production in
the Montanide and AS02 groups suggesting a pro-Th1 response,
although statistically non-significant. Interestingly, the additional
third immunisation generally did not lead to a further increase in
IFNc or IL-5 production or in lymphocyte proliferation. Rather,
many volunteers showed a reduction in the response after the third
immunisation. This difference could not be explained by inter-test
variability. It remains to be investigated if it indicates a shift in the
relative balance between immediate effector cells and long-lived
memory cells.
Although this phase I trial is limited with respect to the size and
generalizibility to the target population, it met its objectives to
outline a generalizable safety profile. Specifically the direct
comparison of the safety profile of different adjuvants is valuable
for future development of AMA1 and other malaria vaccines.
Furthermore, the malaria vaccine candidate AMA1 provides the
possibility of assessing functionality of the immune response by a
parasite growth inhibition assay. However, it must be noted that
the growth inhibition assay is not validated as a correlate of
protection, and is as such a limited predictor for efficacy.
With this study we have shown that the PfAMA1 vaccine
combined with different adjuvants, Alhydrogel
TM, Montanide and
AS02 provided distinct reactogenicity profiles. All vaccine
formulation were immunogenic at both dosages. Growth inhibi-
tion results indicate that induction of functional immune responses
is probably dependent on adjuvant, underscoring the need for
strong immunopotentiators for malaria vaccines. Altogether, these
results are promising for a future development of a PfAMA1
malaria vaccine.
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